Skip to Main Content

Paper Details

Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
Am Heart J
29
2021
Author NameAffiliation
Christopher P CannonBrigham & Women's Hospital and Baim Institute for Clinical Research
Tara I ChangStanford University School of Medicine
Bernard ZinmanLunenfeld-Tanenbaum Research Institute, Mt Sinai Hospital, University of Toronto
Kenneth W MahaffeyStanford Center for Clinical Research, Stanford University School of Medicine
  • 1 - 4

Datasets